Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspartylglucosaminidase is a lysosomal amidohydrolase enzyme responsible for cleaving the bond between asparagine and N-acetylglucosamine in N-linked glycoproteins during the final steps of lysosomal degradation. It is synthesized as a single precursor chain, which undergoes post-translational cleavage to produce α and β subunits that assemble into a functional heterotetramer. Deficiency of this enzyme activity, typically due to mutations in the AGA gene, leads to aspartylglucosaminuria—a lysosomal storage disorder characterized by progressive intellectual disability and motor impairments resulting from disrupted glycoprotein catabolism and subsequent accumulation in neural and other tissues[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aspartylglucosaminidase (AGA).